Imatinib biotransformation

Published: 9 November 2021| Version 1 | DOI: 10.17632/nwgr32rh86.1
Contributor:
Žiga Tkalec

Description

Imatinib is a selective tyrosine kinase inhibitor used to treat chronic myeloid leukemia. It enters the environment by excretion from the body through urine and feces and is transferred with wastewater to a wastewater treatment plant. There, it can be degraded by activated sludge, forming a number of biotransformation products. Presence of imatinib and its potential transformation products in the environment can impose a high risk to aquatic organisms and human health, therefore it is important to obtain knowledge of its environmental fate. The data presented here is a result of a simulated biodegradation of imatinib at two levels of activated sludge using batch biotransformation setup, with and without carbon source. The data was acquired with UPLC-HRMS/MS and processed by MzMine2.36 (Tkalec et al., 2021). The dataset presents a table of [M+H]+ features with retention times and corresponding MS/MS data. With development of new data mining tools this data can be used to identify new transformation products of imatinib and with it fully understand its environmental fate and the risk associated with its presence in the environment.

Files

Categories

Analytical Chemistry, Environment and Health, Cytostatic, Environmental Fate

License